Profusa has launched a research-use-only version of its Lumee tissue oxygen monitoring system, marking the company’s first step into commercial revenue generation through the contract research organisation market.

The California-based digital health company said the Lumee tissue oxygen system is now commercially available as a research-use-only product and service platform, allowing CROs to integrate the technology into existing preclinical and translational research workflows. The launch represents a commercial expansion rather than a clinical or regulatory milestone and is positioned as a revenue-generating initiative.

Profusa is targeting CROs supporting pharmaceutical and biotechnology companies that are seeking continuous, real-time biological data to inform drug development decisions. The company said its Lumee tissue oxygen products are ready for immediate deployment, enabling CRO partners to offer additional services without significant changes to study design or infrastructure.

The global pharmaceutical CRO market was valued at approximately $47.9 billion in 2025 and is forecast to grow at more than 7% annually, driven by rising R&D investment and increasing use of new approach methodologies in drug development. Profusa is positioning its tissue oxygen monitoring system as a tool to support these trends by providing continuous measurements that go beyond traditional endpoint assays.

The Lumee tissue oxygen system is based on Profusa’s tissue-integrated biosensor technology and is designed to measure oxygenation continuously in biological systems. Under the new commercial model, the company will supply research-use-only kits as well as a service-enabled platform for CRO partners, allowing the technology to be incorporated into a range of research settings.

According to Profusa, the system can be applied across advanced in vitro models, organ-on-chip platforms, preclinical pharmacology and toxicology studies, and translational research programmes. The company also highlighted its potential use in research areas where oxygen dynamics play a critical role, including wound healing and tumour microenvironments in oncology.

To support the commercial rollout, Profusa has appointed Sean Givens to lead its government and healthcare research business. He said the launch builds on earlier validation work and existing industry interest in the platform.

“This is a natural and timely extension of Profusa’s platform building off of previous successes of this market,” Givens said: “Our sensors are validated, ready to ship, and already generating strong interest across the industry. By partnering with CROs, we can help accelerate better drug development decisions while creating a meaningful, near-term revenue stream for Profusa.”

The company said the Lumee research offering is intended for non-clinical use and is not being positioned as a diagnostic or therapeutic product. Instead, it is aimed at enabling pharmaceutical and biotech customers to access more biologically relevant data earlier in development, potentially supporting compound selection and study design.

Profusa added that it expects demand for advanced biosensing technologies to increase as CROs look to differentiate their service offerings in a competitive market. The company has not disclosed pricing or revenue projections for the Lumee research-use-only system.